Dow Up0.35% Nasdaq Down0.02%

The Medicines Company (MDCO)

-NasdaqGS
25.93 0.41(1.56%) Aug 20, 4:00PM EDT
ProfileGet Profile for:
The Medicines Company
8 Sylvan Way
Parsippany, NJ 07054
United States - Map
Phone: 973-290-6000
Fax: 973-656-9898
Website: http://www.themedicinescompany.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Drugs - Generic
Full Time Employees:571

Business Summary 

The Medicines Company provides medical solutions for patients in acute and intensive care hospitals worldwide. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for use in patients undergoing percutaneous coronary intervention; Recothrom, a human recombinant thrombin used as an aid to hemostasis; Cleviprex, an intravenous small molecule calcium channel blocker for blood pressure reduction; Minocin IV, an antibiotic for the treatment of infections due to gram-negative bacteria, including Acinetobacter species; and ready-to-use formulation of Argatroban for the treatment of thrombosis. Its products under development include Cangrelor, an intravenous small molecule antiplatelet agent for the prevention of platelet activation and aggregation; Oritavancin, an investigational intravenous antibiotic for the treatment of acute bacterial skin related infections; and IONSYS, a pre-registration stage product for the short-term management of acute postoperative pain. The company’s products under development also comprise Fibrocaps, which is used as an aid to stop bleeding during surgery; RPX-602 for the treatment of infections; MDCO-216, a novel biologic product to reverse atherosclerotic plaque development and reduce the risk of coronary events in patients with ACS; Carbavance, an antibiotic agent for the treatment of hospitalized patients with bacterial infections; and ALN-PCSsc, a subcutaneously administered RNA interference therapeutic for the treatment of hypercholesterolemia. In addition, it offers acute care generic products for use in the cardiovascular and neurocritical care; and promotes BRILINTA, an oral tablet antiplatelet medicine. The company has collaborations with Alnylam Pharmaceuticals, Inc. and AstraZeneca LP. The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on The Medicines Company

Corporate Governance 
The Medicines Company’s ISS Governance QuickScore as of Aug 1, 2014 is 5. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 5; Compensation: 7.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Dr. Clive A. Meanwell M.D., Ph.D., 56
Chairman and Chief Exec. Officer
1.64M1.09M
Mr. Glenn P. Sblendorio , 58
Pres, Chief Financial Officer, Treasurer and Director
1.06M2.71M
Mr. William B. O'Connor , 55
Chief Accounting Officer and Sr. VP
639.00K1.38M
Mr. Glyn R. Parkin ,
Sr. VP of International Operations
N/AN/A
Mr. David C. Mitchell , 60
VP of Information Technology & Information Systems
N/AN/A
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders